Literature DB >> 27661436

HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).

Mingtao Liu1, Jennie Wang2, Paul Liu3.   

Abstract

An HPLC method for the assay of an anticancer nucleoside, 4'-thio-2'-deoxycytidine (T-dCyd, NSC 764276), has been developed and validated. The stress testing of T-dCyd was carried out in accordance with ICH guidelines Q1A (R2) under acidic, alkaline, oxidative, thermolytic, and photolytic conditions. The separation of T-dCyd from its impurities and degradation products was achieved in 40min on a Luna® Phenyl-Hexyl column (150mm×4.6mm i.d., 3μm) with a gradient elution using ammonium phosphate buffer (pH 3.85) and methanol as the mobile phase. The gradient starts from 2% and ends at 80% of methanol. Detection is by UV at 282nm. LC-QTOF/MS was used to obtain mass data for characterization of impurities and degradation products. The proposed HPLC assay method was validated for specificity, linearity (concentration range 0.25-0.75mg/mL, r≥0.9998), accuracy (recovery 98.1-102.0%), precision (RSD≤1.5%), and sensitivity (LOD 0.1μg/mL). The developed method was suitable for the quality control and stability monitoring of the T-dCyd drug substance.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4′-thio-2′-deoxycytidine; Forced degradation; HPLC validation; Impurity and degradation product characterization; NSC 764276; T-dCyd

Mesh:

Substances:

Year:  2016        PMID: 27661436      PMCID: PMC5063648          DOI: 10.1016/j.jpba.2016.08.034

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  21 in total

1.  Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.

Authors:  Jan H Beumer; Erin Joseph; Merrill J Egorin; Joseph M Covey; Julie L Eiseman
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-12-20       Impact factor: 3.205

Review 2.  Mammalian cytosine methylation at a glance.

Authors:  Steen K T Ooi; Anne H O'Donnell; Timothy H Bestor
Journal:  J Cell Sci       Date:  2009-08-15       Impact factor: 5.285

Review 3.  Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology.

Authors:  Victor E Marquez; Joseph J Barchi; James A Kelley; Kambhampati V R Rao; Riad Agbaria; Tsipi Ben-Kasus; Jonathan C Cheng; Christine B Yoo; Peter A Jones
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2005       Impact factor: 1.381

Review 4.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

5.  DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1).

Authors:  S Milutinovic; J D Knox; M Szyf
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

6.  Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme.

Authors:  Katan Patel; Jacqueline Dickson; Shahida Din; Kenneth Macleod; Duncan Jodrell; Bernard Ramsahoye
Journal:  Nucleic Acids Res       Date:  2010-03-25       Impact factor: 16.971

7.  Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.

Authors:  J A Secrist; K N Tiwari; J M Riordan; J A Montgomery
Journal:  J Med Chem       Date:  1991-08       Impact factor: 7.446

8.  Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

Authors:  Jan H Beumer; Robert A Parise; Edward M Newman; James H Doroshow; Timothy W Synold; Heinz-Josef Lenz; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-26       Impact factor: 3.333

Review 9.  Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?

Authors:  Stephen B Baylin; Joyce E Ohm
Journal:  Nat Rev Cancer       Date:  2006-02       Impact factor: 60.716

10.  Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.

Authors:  Qun Zhou; Agoston T Agoston; Peter Atadja; William G Nelson; Nancy E Davidson
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

View more
  1 in total

Review 1.  5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development.

Authors:  William B Parker; Jaideep V Thottassery
Journal:  J Pharmacol Exp Ther       Date:  2021-09-09       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.